These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 31434110)
21. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum]. Škapa P; Dundr P Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446 [TBL] [Abstract][Full Text] [Related]
22. Should I Be Tested for BRCA Mutations? Jin J JAMA; 2019 Aug; 322(7):702. PubMed ID: 31429898 [No Abstract] [Full Text] [Related]
23. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502 [TBL] [Abstract][Full Text] [Related]
24. Clinical characteristics and choices regarding risk-reducing surgery in BRCA mutation carriers. Stuckey A; Dizon D; Scalia Wilbur J; Kent J; Tejada-Berges T; Gass J; Legare R Gynecol Obstet Invest; 2010; 69(4):270-273. PubMed ID: 20090358 [TBL] [Abstract][Full Text] [Related]
25. Disparities between Uptake of Germline Hur YM; Mun J; Kim MK; Lee M; Kim YH; Kim SC J Korean Med Sci; 2021 Oct; 36(38):e241. PubMed ID: 34609091 [TBL] [Abstract][Full Text] [Related]
26. Surgical risk-reduction in carriers of BRCA mutations: where do we go from here? Kauff ND; Barakat RR Gynecol Oncol; 2004 May; 93(2):277-9. PubMed ID: 15099933 [No Abstract] [Full Text] [Related]
27. US court reverses gene patent ruling for BRCA1 and BRCA2. Brower V Lancet Oncol; 2011 Sep; 12(9):835. PubMed ID: 21984989 [No Abstract] [Full Text] [Related]
28. Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea. Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS Cancer Res Treat; 2020 Oct; 52(4):1229-1241. PubMed ID: 32718143 [TBL] [Abstract][Full Text] [Related]
29. Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years. Weiss AS; Swisher E; Pennington KP; Radke M; Khasnavis N; Garcia RL; Kilgore MR; Lee MK; Norquist BM Gynecol Oncol; 2020 Oct; 159(1):214-220. PubMed ID: 32709535 [TBL] [Abstract][Full Text] [Related]
30. Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations. Solsky I; Chen J; Rebbeck TR Gynecol Oncol; 2020 Feb; 156(2):363-376. PubMed ID: 31918993 [TBL] [Abstract][Full Text] [Related]
31. Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome. Mitamura T; Sekine M; Arai M; Shibata Y; Kato M; Yokoyama S; Yamashita H; Watari H; Yabe I; Nomura H; Enomoto T; Nakamura S; Jpn J Clin Oncol; 2020 Dec; 50(12):1380-1385. PubMed ID: 32676635 [TBL] [Abstract][Full Text] [Related]
33. [Peculiarities of diagnosis, treatment and prevention of hereditary cancer of the breast and ovary. Clinical and genetic screening among BRCA1/2 mutation carriers and individuals with high family risk of cancer]. Rumiantseva UV; Rumiantsev PO; Kiseleva MV Vopr Onkol; 2008; 54(3):251-9. PubMed ID: 18652227 [No Abstract] [Full Text] [Related]
34. [Genetic testing in patients at risk for carcinoma of the breast]. Kiechle M Dtsch Med Wochenschr; 2006 Oct; 131(43):2420-2. PubMed ID: 17054060 [No Abstract] [Full Text] [Related]
35. Reclassification of Ha HI; Ryu JS; Shim H; Kong SY; Lim MC J Gynecol Oncol; 2020 Nov; 31(6):e83. PubMed ID: 33078592 [TBL] [Abstract][Full Text] [Related]
36. BRCA1/2 germline testing in non-mucinous epithelial ovarian carcinoma: changing international practice and implications for service provision. Coakley M; Cleary V; Power N; O'Reilly S Eur J Hum Genet; 2017 Feb; 25(2):167-168. PubMed ID: 27759028 [No Abstract] [Full Text] [Related]
37. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome. Shulman LP Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261 [TBL] [Abstract][Full Text] [Related]
38. Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas. Somasegar S; Weiss AS; Norquist BM; Khasnavis N; Radke M; Manhardt E; Pennil C; Pennington KP; Eckert MA; Chryplewicz A; Lengyel E; Swisher EM Gynecol Oncol; 2021 Oct; 163(1):130-133. PubMed ID: 34452747 [TBL] [Abstract][Full Text] [Related]
39. Can personality traits affect the quality of life of women with the BRCA1/BRCA2 mutations before and after prophylactic adnexectomy? Stanisz M; Schneider-Matyka D; Panczyk M; Branecka-Woźniak D; Kurzawa R; Knyszyńska A; Grochans E Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12342-12349. PubMed ID: 33336754 [TBL] [Abstract][Full Text] [Related]
40. Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study. Lertkhachonsuk AA; Suprasert P; Manchana T; Kittisiam T; Kantathavorn N; Chansoon T; Khunamornpong S; Pohthipornthawat N; Tangjitgamol S; Luasiripanthu T; Teerapakpinyo C; Shuangshot S; Iemwimangsa N; Chantratita W Asian Pac J Cancer Prev; 2020 Aug; 21(8):2381-2388. PubMed ID: 32856869 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]